Highest-materiality recent filing
Quanterix shareholders reject amendment and restatement of 2017 equity incentive plan
Shareholders did not approve Proposal 4 (amend/restate 2017 Plan through June 2031); 9,677,232 for vs 24,004,124 against.
Quanterix appoints Jason Faessler as CFO effective June 22, 2026
Faessler previously served as SVP of Finance at Bruker Corporation, leading global FP&A and Americas finance.
Quanterix appoints Anthony Catalano as COO; Michael Miller transitions to CTO/Products Officer
Catalano appointed COO effective May 14, 2026; previously SVP at Flagship Pioneering and Akoya.
Quanterix CFO Vandana Sriram to depart June 15, 2026; search underway
CFO Vandana Sriram to leave effective June 15, 2026; severance includes 12 months base salary, 2026 target bonus, health benefits.
Quanterix Q1 revenue $36.4M (+20% YoY); reaffirms FY2026 guidance of $169-174M
Revenue of $36.4M, up 20% YoY; GAAP gross margin 42.7%, adjusted 50.9%.
Quanterix Q4 revenue $43.9M (+25% YoY); guides 2026 rev $169-174M, cash flow breakeven H2
Q4 revenue $43.9M vs $35.2M prior year (+25%); full-year revenue $138.9M (+1% YoY).
Quanterix appoints Everett Cunningham as CEO; expects to exceed FY2025 revenue and cash guidance
Masoud Toloue steps down effective Jan 19; receives accelerated equity vesting through Apr 30, 2026, options exercisable until Dec 31, 2026.
Quanterix appoints Hampton, Sachs to board; Donnelly named Executive Chair
Garret Hampton (ex-Thermo Fisher) and Alan Sachs (ex-Thermo Fisher CMO) join board effective Nov. 20, 2025.
Quanterix Q3 revenue $40.2M (+12.3% YoY); gross margin drops to 42.8%
GAAP gross margin 42.8% (prior year 56.3%); adjusted gross margin 45.9% (prior 50.7%).
Elected Myla Lai-Goldman, Masoud Toloue, David Walt as directors for 3-year terms; broker non-votes ~4.3M.
Quanterix adjourns annual meeting; supermajority vote amendments need more votes
Annual meeting convened and adjourned without business; reconvened Sept 29, 2025 at 10am ET.
Quanterix files pro forma financials for Akoya acquisition; combined net loss $74.6M in H1 2025
Pro forma combined net loss for H1 2025: $74.6M ($1.61 EPS); FY2024: $101.2M ($2.21 EPS).
Quanterix Q2 revenue drops 29% to $24.5M; net loss widens to $30M; guides FY25 revenue $130-135M
GAAP net loss $30.0M vs $7.4M in Q2 2024; GAAP gross margin 46.2% vs 64.7%.
Kent Lake withdraws its director nominations and will support the Board's candidates at the 2025 annual meeting.
Quanterix commits to workforce reduction targeting $18M annual savings post-Akoya integration
Termination plan committed July 18, 2025, to reduce operating costs and preserve cash.
Terminating certain Akoya executives under its Executive Severance Plan as part of integration.
Quanterix completes Akoya acquisition for ~7.8M shares + $20M cash; TAM expands to $5B
Quanterix issued ~7.8M shares and paid ~$20M cash to buy Akoya, creating integrated blood & tissue biomarker platform.
Quanterix sets 2025 annual meeting for Sept 23; updates proposal deadlines
Annual meeting will be held virtually on September 23, 2025 at 9:00 a.m. ET.
Quanterix dismisses EY, hires KPMG as auditor; cites material weaknesses and restatement
EY dismissed effective after Q1 2025 10-Q filing; Audit Committee selected KPMG for FY 2025 after RFP.
Quanterix Q1 revenue down 5% to $30.3M, net loss widens; approves $30M annual cost cuts
Revenue $30.3M (-5% YoY); GAAP net loss $20.5M vs $11.2M prior year.
Per Akoya share, stockholders receive 0.1461 Quanterix shares plus $0.38 cash; aggregate cash capped at $20M.
Quanterix agrees to provide Akoya up to $30M in convertible notes pending merger close
Convertible notes up to $30M aggregate principal; draw period runs May 15, 2025 to July 9, 2025 (or Jan 9, 2026 if merger extended).
Quanterix appoints William Donnelly Chairman; Director Madaus resigns after majority vote loss
William P. Donnelly appointed Chairman of the Board effective March 24, 2025.
Quanterix Q4 2024 revenue $35.2M (+11% YoY); FY 2025 guidance $140-146M
Q4 revenue $35.2M, up 11% YoY; net loss $11.6M vs $8.8M prior year.
Quanterix highlights Akoya acquisition benefits; responds to Kent Lake director nominations
Acquisition unlocks $5B addressable market in spatial biology and $10B Alzheimer's diagnostics opportunity.
Quanterix and Akoya merger receives HSR clearance; waiting period expired Feb 24
Hart-Scott-Rodino waiting period expired at 11:59 p.m. ET on February 24, 2025.
Quanterix adopts 2025 AIP with CEO target of $675K and CFO target of $325.5K
Compensation Committee approved 2025 annual cash incentive plan on January 27, 2025.
Quanterix reports preliminary Q4 revenue $34.9M, FY 2024 revenue $137.2M, up 12% YoY
Q4 2024 revenue ~$34.9M, +11% YoY; Accelerator up 22% to $8.6M, Instruments down 6% to $3.1M.
Quanterix to acquire Akoya Biosciences in stock deal; exchange ratio 0.318
Akoya shareholders to receive 0.318 Quanterix shares per share; no cash consideration except for fractional shares.
Quanterix to acquire Akoya Biosciences; expands addressable market to $5B
Transaction expected to close in Q2 2025; combined cash at close ~$175M.
Quanterix completes acquisition of Emission Inc. for up to $70M total
Upfront cash payment of $10M; additional $10M payable upon technical milestones.
Quanterix acquires EMISSION for $10M upfront, up to $70M total, expanding bead technology
Upfront $10M cash; additional $10M on technical milestones; up to $50M earnout through 2029 based on performance.
Quanterix receives Nasdaq delinquency notice for delayed Q3 10-Q filing due to restatement
Notice received Nov 21; Company has until Jan 20, 2025 to submit compliance plan; may get extension to May 13, 2025.
Quanterix restates prior financials for inventory errors; Q3 revenue $35.7M (+13% YoY)
Revenue $35.7M (+13% YoY); GAAP gross margin 58.9%; reaffirms FY2024 revenue guidance $134-138M.
Quanterix appoints Jeffrey T. Elliott to Nominating and Governance Committee
Jeffrey T. Elliott appointed to Nominating and Governance Committee effective October 2, 2024.
Quanterix appoints Ivana Magovčević-Liebisch, Ph.D., J.D. to Board of Directors
Dr. Magovčević-Liebisch appointed effective Oct 2, 2024 as Class III director with term expiring at 2026 annual meeting.
Jeffrey Elliott appointed to Quanterix board; brings Exact Sciences experience
Appointed effective August 19, 2024 as a Class I director with term expiring at 2027 annual meeting.
Quanterix Q2 revenue up 11% to $34.4M; net loss widens to $9.5M; cuts FY2024 revenue guidance
Revenue $34.4M (+10.8% YoY); GAAP gross margin 58.3% vs 61.7% prior year.
Quanterix stockholders elect directors, approve say-on-pay, ratify auditor at 2024 annual meeting
Karen A. Flynn and Martin D. Madaus elected as independent directors for three-year terms.
Quanterix appoints Michael Miller as COO; prior COO Daniel Pikora resigns
Michael Miller, age 60, appointed COO effective May 21, 2024, succeeding Daniel Pikora who resigned.
Quanterix Q1 revenue $32.1M (+12.7%); net loss $10.1M; FDA breakthrough for P-tau217 test
Revenue $32.1M (+12.7% YoY); net loss $10.1M (increase of $4.0M YoY).
Quanterix enhances CEO & CFO severance benefits; director Olson not seeking re-election
Director Laurie Olson will not stand for re-election at June 3, 2024 Annual Meeting; no disagreement with company.
Quanterix Q4 revenue up 22% to $31.5M, net loss narrows; guides FY2024 revenue $139-144M
Q4 revenue $31.5M (+22% YoY); GAAP gross margin 53.2% (up from 48.8%); net loss $12.4M vs $18.6M.
Quanterix reschedules Q4/FY 2023 earnings call to Feb 29; reaffirms guidance
Earnings call moved from Feb 26 to Feb 29, 2024 to align with 10-K filing deadline.
Quanterix sets 2024 bonus targets and amends CEO/CFO severance
CEO Masoud Toloue target award $650,000; CFO Vandana Sriram target $312,312 under 2024 AIP.
Quanterix reports preliminary FY2023: double-digit revenue growth, non-GAAP GM ~50%, >$300M net cash
Preliminary FY2023 double-digit revenue growth; GAAP gross margin in high 50's, non-GAAP ~50% (improvement of 1200 bps).
Quanterix Q3 revenue $31.3M (+18% YoY), net loss narrows; raises full-year guidance
Q3 revenue $31.3M (+18% YoY); GAAP net loss narrowed to $7.8M from $35.1M.
Quanterix appoints William P. Donnelly to Board of Directors
Donnelly, former EVP and CFO of Mettler-Toledo, appointed effective August 17, 2023.
Quanterix appoints Vandana Sriram CFO effective Aug 21; Doyle retires Mar 2024
Vandana Sriram becomes CFO on August 21, 2023, replacing Michael Doyle who moves to Executive Director, Finance until retirement.
Revenue $31.0M, +32% YoY, including $1.5M one-time product/license benefit; 9% sequential growth.
The Board of Directors of Quanterix Corporation (the "Company") has appointed Jason Faessler as the Chief Financial Officer and Treasurer of the Company.
On May 14, 2026, Anthony Catalano was appointed as the Chief Operating Officer of Quanterix Corporation (the “Company”).
Michael Miller, formerly the Chief Operating Officer of the Company, has transitioned to a new role as the Chief Technology and Products Officer of the Company.
Vandana Sriram will be leaving Quanterix Corporation (the “Company”) and will no longer serve as the Chief Financial Officer and Treasurer of the Company effective June 15, 2026.
On March 27, 2025, Dr. Madaus notified the Board of his intention to resign from the Board and each committee of the Board on which he serves no later than the date of the Company's 2025 annual meeting of stockholders
On March 24, 2025, the board of directors (the "Board") of Quanterix Corporation (the "Company") appointed William P. Donnelly to serve as Chairman of the Board, effective immediately.
appointed Ivana Magovčević-Liebisch, Ph.D., J.D. to serve on the Board effective immediately.
On August 19, 2024, the board of directors (the “Board”) of Quanterix Corporation (the “Company”) appointed Jeffrey T. Elliott to serve on the Board effective immediately.
On May 21, 2024, Michael Miller, age 60, was appointed as Chief Operating Officer of Quanterix Corporation
Daniel Pikora, former Chief Operating Officer, who resigned from the role on May 21, 2024 and will pursue opportunities outside the Company.
On May 2, 2024, Brian J. Blaser notified Quanterix of his resignation from its Board of Directors, effective as of May 3, 2024.
received notice from director Laurie Olson that she will not stand for re-election at the Company’s 2024 Annual Meeting of Stockholders, which is expected to be held on June 3, 2024.
Max materiality 0.90 · Median 0.60 · Most common event earnings